MedKit Development For Flu Is “Part Of The Discussion”– Sharfstein
This article was originally published in The Pink Sheet Daily
FDA’s response to the H1N1 influenza does not include making antivirals available for home stockpiling, acting FDA commissioner says.
You may also be interested in...
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.
Kind’s Specific Ingredient Claims Remain Airborne After General Comparison To Clif Bar Line Grounded
National Advertising Division says a TV commercial Kind previously aired claiming “75% less sugar than the leading Clif bar” made an unfair “line claim.” But Kind says "ultimately this issue is moot" as it stopped using the "commercial (which takes place on an airplane) many months ago in light of the COVID-19 pandemic.”